Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant

Inclusion Criteria: * Diagnosis: hematologic malignancies/disorders including aplastic anemia and myelodysplastic syndrome * Procedure: first allogeneic, T cell-replete transplantation of stem-cells from peripheral blood or bone marrow of an human leukocyte antigen (HLA) matched, unrelated or nonsyngeneic sibling donor * CMV seropositive donor and/or recipient * Performance level: must have already been determined to be eligible for HCT at City of Hope (COH) * Organ function requirements: The minimum organ function requirements should be the same as the requirements for HCT * Informed Consent: All patients must be capable of signing a written informed consent and no consent can be provided by a legal guardian Exclusion Criteria: * The recipient had prior polymerase chain reaction (PCR) positive CMV infection in blood or organ-specific disease in the past 12 months * The source of hematopoietic stem cells is T-cell depleted * Concomitant anti-graft-versus-host disease (GVD) treatment includes in vivo T cell depletion * Recipient is human immunodeficiency virus (HIV)-1 positive * No prior allogeneic HCT (Allo HCT) (autologous HCT \[Auto HCT\] is allowed)